While there are only two sides to the cost-benefit equation, each has a number of components baked in. On the cost side, increasingly sophisticated cell-based and other immunotherapies can be expensive to manufacture and deliver, and supportive and other resource-based care costs incurred by providers must also be factored in. Different markets (e.g., US vs. UK and different EU regions) have adopted varying stances, but all are applying an increasingly restrictive stance on how much companies can charge. On the benefit side, therapeutic candidates must outperform in their indications both against current and evolving standards of care. While clinical performance is difficult to predict beforehand, optimal positioning strategy is required to ensure maximal unlocking of value from these complicated therapeutic technologies in order to ensure healthy margins, both in cancer patients and the balance sheet.
- Joel Sandler, PhD, Principal, Cancer Cell Therapy Practice Lead, Commercial BioConsulting, Lumanity
- Gregory Fiore, MD, CEO, Exacis Biotherapeutics
- Daniel Gladwell, Chief of HTA Strategy, HEOR, Lumanity
- Maurits Geerlings, MD, MBA, CEO, NanoCell Therapeutics, Inc.
- Jason Litten MD, Chief Medical Officer, Artiva Biotherapeutics
- Peretz Partensky, PhD, CEO, ImmuneBridge
- Ramon Tiu, MD PhD, Cell Therapy Lead, Takeda
- Satish Valluri, Janssen